Skip to content
Screener

Repligen RGEN Royalty — Revenue (Gross)

Other product segments

Proteins Products
$97.44M+30.9%
Process Analytics Products
$81.24M+37.0%

Similar metrics at other companies

Rambus logo
RMBSRoyalty — Revenue (Gross)
$84.26M+22.8%
Caleres logo
CALLicense And Royalty — Revenue (Gross)
$2.03M+5.7%
WisdomTree logo
WTOther Revenues — Revenue (Gross)
$19.53M+108%
Gencor Industries logo
GENCOther Revenues — Revenue (Gross)
$474K-6.1%
Atlanticus Holdings Corporation logo
ATLCInterchange Revenues Other Revenue — Revenue (Gross)
$15.07M+152%
Hitachi logo
HITRevenues From Fees — Revenue (Gross)
$6.7M+107%

Other financials

Income statement

See full
Revenue$204.1M+11.9%
Gross profit$110.0M+20.7%
Operating income$14.0M+0.6%
Net income$5.0M-66.3%
EPS (diluted)$0.09-65.4%

Balance sheet

See full
Cash & equivalents$606.8M-14.4%
Total debt$690.9M+354%
Total equity$2.1B+2.4%
Total assets$3.0B+1.7%

Cash flow

See full
Operating cash flow$32.8M+14.5%
CapEx$5.3M-24.9%
Free cash flow$27.4M+27.5%

Valuation

See full
Market cap$8.95B+42.1%
Enterprise value$9.03B+57.3%
P/E215.5×—
P/S11.6×+0.3×

Profitability

See full
Gross margin47.6%+0.9pp
Operating margin15.6%-11.0pp
Net margin17.3%-3.5pp
FCF margin22%+6.9pp

Returns & leverage

See full
Return on equity2%+1.6pp
Debt / equity0.3×+0.3×
Current ratio9.1×+0.5×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Repligen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323773
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue:
Product$204,085$182,329$398,296$351,466
Royalty and other revenue43378772
Total revenue204,128182,366398,383351,538
Costs and operating expenses:
Cost of goods sold94,09189,371180,062167,172
Research and development14,41713,97028,87526,084
Selling, general and administrative76,61870,906153,154141,612

ITEM 1. Financial Statements

FAQ

What is Repligen's royalty — revenue (gross)?
Repligen (RGEN) reported royalty — revenue (gross) of $43K in Q2 2026.
How has Repligen's royalty — revenue (gross) changed year-over-year?
Repligen's royalty — revenue (gross) increased by 16.2% year-over-year, from $37K to $43K.
What is the long-term trend for Repligen's royalty — revenue (gross)?
Over 4 years (2021 to 2025), Repligen's royalty — revenue (gross) has grown at a 8.3% compound annual growth rate (CAGR), from $215K to $296K.
What does royalty — revenue (gross) mean?
This metric represents the total gross revenue generated from licensing intellectual property or proprietary bioprocessing technologies to third-party partners. It reflects the income streams derived from the commercialization of the company's patented innovations within the biopharmaceutical manufacturing ecosystem. Monitoring this figure helps investors assess the long-term value and market adoption of the company's technology portfolio independent of direct product sales.

Ask your AI about Repligen's royalty — revenue (gross).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude